Idelalisib
Cat. No.：YN420148
CAS No. ：870281-82-6
规格
价格(RMB)
库存
| 产品名称: | Idelalisib |
| CAS No.: | 870281-82-6 |
| Chemical Name: | 5-fluoro-3-phenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]-4(3H)-quinazolinone |
| Synonyms: | 艾代拉里斯; CAL-101; GS-1101 |
| 分子量: | 415.42 |
| 分子式: | C₂₂H₁₈FN₇O |
| SMILES: | O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)CC)=NC5=C1C(F)=CC=C5 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Idelalisib (CAL-101; GS-1101) 是一种口服有效的高选择性p110δ抑制剂，IC50为 2.5 nM，比 p110δ 和其他 PI3K class I 酶的选择性高 40 到 300 倍。 |
| IC50和靶点: | [{name:"p110δ:2.5 nM (IC50)"},{name: "p110γ:89 nM (IC50)"},{name: "p110β:565 nM (IC50)"},{name: "p110α:820 nM (IC50)"},{name: "hVps34:978 nM (IC50)"},{name: "DNA-PK:6729 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Hennessy, B.T., Smith, D.L., Ram, P.T., et al.Exploiting the PI3K/AKT pathway for cancer drug discoveryNat. Rev. Drug Discov.4(12),988-1004(2005)
Hirsch, E., Ciraolo, E., Ghigo, A., et al.Taming the PI3K team to hold inflammation and cancer at bayPharmacol. Ther.118(2),192-205(2008)
Lannutti, B.H., Meadows, S.A., Hermann, S.E.M., et al.CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viabilityBlood117(2),591-594(2011)
Hoellenriegel, J., Meadows, S.A., Sivina, M., et al.The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemiaBlood118(13),3603-3612(2011)
